2-fluoro-2-deoxy-sorbitol

2-fluoro-2-deoxy-sorbitol (commonly utilized in its fluorine-18 radiolabeled form, [18F]2-fluoro-2-deoxy-sorbitol or [18F]FDS) is a diagnostic radiopharmaceutical and sorbitol analog developed by Johns Hopkins University. It is designed as a pathogen-specific imaging agent for positron emission tomography (PET) to detect and localize infections caused by Enterobacterales (Gram-negative bacteria) and invasive mold infections (such as Aspergillus, Rhizopus, and Mucor). Unlike mammalian cells, these pathogens possess specific phosphotransferase systems (PTS) and sorbitol-metabolizing enzymes (such as sorbitol-6-phosphate dehydrogenase and sorbitol dehydrogenase) that actively transport and phosphorylate [18F]FDS, trapping it intracellularly. Additionally, [18F]FDS has been evaluated as a functional renal imaging agent to measure glomerular filtration rate (GFR) due to its rapid renal clearance, and as a paracellular marker to non-invasively monitor blood-brain barrier (BBB) permeability in neuroinflammatory and neurodegenerative conditions.

Other names

[18F]2-deoxy-2-fluoro-D-sorbitol[18F]2-fluoro-2-deoxy-sorbitol[18F]FDS[18F]fluorodeoxysorbitol18F-FDS2-[18F]-fluorodeoxysorbitol2-deoxy-2-[18F]fluoro-D-sorbitol2-deoxy-2-fluoro-D-sorbitol2-deoxy-2-fluorosorbitolFDSfluorine-18 fluorodeoxysorbitolfluorine18 fluorodeoxysorbitolfluorine 18 fluorodeoxysorbitolfluorodeoxysorbitol